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http:WHAT THIS PAPER ADDS
This prospective analysis reports rates of acute kidney injury (AKI) after elective endovascular aneurysm repair,
using consistent contemporary deﬁnitions. It suggests that the rate of AKI is high and is associated with medium-
term outcome after this procedure. As a result, pre-operative planning and peri-operative care should ensure
that appropriate preventive strategies are applied.Background: Acute kidney injury (AKI) is an important post-operative complication that may impact on mortality,
morbidity, and cost. The incidence after endovascular aneurysm repair (EVAR) remains unknown, as the current
literature has not employed consistent deﬁnitions. The aim of this study is to assess the incidence of AKI after
elective EVAR and examine the impact of AKI on mortality and cardiovascular morbidity using the current
universally accepted deﬁnitions.
Methods: This was a cohort study using prospectively collected data, including consecutive patients undergoing
elective EVAR for an infrarenal abdominal aortic aneurysm (AAA). Those with end stage renal failure were
excluded. The primary endpoint was incidence of AKI as per the “Acute Kidney Injury Network” (AKIN), and
“Kidney Disease Improving Global Outcomes” (KDIGO) criteria. Secondary endpoints included AKI stage, drop in
estimated glomerular ﬁltration rate (eGFR), and mortality and cardiovascular morbidity.
Results: 149 patients were included (16 females, 11%; mean age: 69  8 years; mean AAA diameter:
6.0  1.1 cm), 28 (18.8%) of whom developed AKI (26 patients classiﬁed as stage 1 and 2 as stage 2). Within 48
hours, those with AKI dropped their eGFR from 61  20 mL/kg/1.73 m2 to 51  20 units (p < .001), and those
without from 75  9 to 74  10 units (p < .001). None required dialysis during a 33  11 month follow up.
Development of AKI was associated with mortality (HR 0.035, 95% CI: 0.005 to 0.240, p < .001) and
cardiovascular morbidity (HR: 0.021, 95% CI: 0.004 to 0.11, p < .001) on adjusted regression analysis.
Conclusions: The incidence of AKI after EVAR is signiﬁcant and is independently associated with medium-term
mortality and morbidity.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Abdominal aortic aneurysm (AAA) constitutes a serious
health problem; current prevalence for men above the age
of 65 ranges from 2% to 7%.1e3 Endovascular abdominal
aortic aneurysm repair (EVAR) is now a ﬁrst line treatment,
as early and medium-term outcomes have proven similar or
superior to open repair.4 However, those undergoing EVAR
are at risk of developing acute kidney injury (AKI) for several
reasons. Acute kidney injury after any type of surgical orresponding author. A. Saratzis, University Hospital Coventry and
kshire, Coventry CV2 2DX, UK.
il address: a_saratzis@yahoo.gr (A. Saratzis).
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//dx.doi.org/10.1016/j.ejvs.2015.01.002radiological intervention is independently associated with
higher morbidity, prolonged length of hospital stay, cost,
and short-term mortality (even as high as 20%).5e7 Long-
term survival is also directly affected by AKI in patients
undergoing vascular operations.8e12 The incidence of AKI
after elective EVAR is practically unknown as a uniform
widely accepted deﬁnition of AKI has never been used
consistently in the current literature.13e17 Most in-
vestigators have not included post-operative urine output in
deﬁning AKI. Instead, serum creatinine (SCr) alone has been
used as a marker of immediate post-operative renal
dysfunction (deﬁned as a rise of more than 25% or 50%)
and then reported as “AKI incidence.” The current deﬁni-
tions of AKI require precise urine output measurements for
48 hours. Several other inconsistent reporting criteria, apart
from SCr levels, have also been applied18 in the EVAR
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glomerular ﬁltration rate (eGFR).18 As a result, the aim of
this cohort study was to assess the prevalence of AKI using
the currently accepted criteria (“Acute Kidney Injury
Network” and “Kidney Disease Improving Global Out-
comes”19,20) after elective EVAR and assess its impact on
medium-term mortality and cardiovascular morbidity.
METHODS
Study design and population
This is a cohort study including patients undergoing elective
EVAR of an infrarenal abdominal aortic aneurysm (AAA)
between September 2010 and September 2013 in a tertiary
referral centre for aneurysm disease. Patients were eligible
for repair if they had an AAA diameter >5.5 cm or an AAA
<5.5 cm with a rapidly increasing sac (>1 cm per year).
Endovascular repair was offered as a ﬁrst line procedure.
Data for patients undergoing EVAR during the aforemen-
tioned period were entered prospectively in an electronic
database, aiming to assess predictors of outcome after
elective EVAR. The original cohort consisted of 249 patients.
Patients were included in the present analysis if they had
serum creatinine (SCr) and hourly urine output measure-
ments for at least 48 hours and all relevant information
available, and were able to provide written informed con-
sent; urine output measurements were not available for 72
patients because of missing documentation and an SCr was
not available for 41 patients at 48 hours, hence the ﬁnal
cohort consisted of 149 patients. Patients with symptom-
atic, leaking, ruptured, infected, or inﬂammatory aneurysms
and patients with end-stage renal disease (ESRD) receiving
renal replacement therapy (at baseline) were excluded.Study protocol
Demographics, comorbidities and anatomical data were
recorded and stored electronically at baseline. All partici-
pants underwent a computed tomographic angiography
(CTA) with 3 dimensional reconstruction before EVAR to
assess aortic anatomy. Blood samples at baseline were
obtained prior to any imaging requiring the administration
of contrast. Further blood samples were taken at 24 and 48
hours after the repair for every patient. A standard follow
up protocol, including laboratory checks at 30 days, 6
months, and 12 months after the operation, and annually
thereafter, was employed. Imaging during follow up
included plain abdominal radiography and a CTA at 6
months, 12 months, and annually thereafter, which was the
standard follow up protocol for EVAR at the time. Since July
2013 patients have undergone follow up with ultrasound
imaging at the same intervals.Endovascular repair procedures
The Anaconda (Vascutek, UK) endograft was deployed in all
cases, adhering to the manufacturer’s instructions for use.
Indications and speciﬁcations have been described else-
where.21 The speciﬁc device does not employ suprarenalﬁxation (such as a bare stent or any other modality that is
deployed above the oriﬁce of the renal arteries). All EVARs
were performed in an operating theatre under general
anaesthesia. Iopromide was used as contrast-medium
(Ultravist 300, Bayer, Berlin, Germany). Prior to EVAR, the
administration of any contrast for at least 2 weeks, and non-
steroidal anti-inﬂammatory drugs (NSAIDs) for at least 1
week, were avoided in all cases. Metformin was dis-
continued for 2 days, where applicable. For patients with a
pre-operative eGFR>60 mL/min/1.73 m2, intravenous ﬂuids
(0.9% saline, 2 mL/kg/hour) were started on the day of the
operation. Patients with an eGFR<60 units were admitted 1
day before and received intravenous ﬂuids (0.9% saline,
1.5 L/24 hours) for 24 hours, until nil by mouth, when they
were commenced on 0.9% saline at 2 mL/kg/hour. Urinary
catheterization and hourly urine output measurements were
routinely employed and patients remained catheterized
until ambulatory. Intra-operative ﬂuid management was
guided by mean arterial pressure, recorded via a peripheral
arterial line. The aim of ﬂuid therapy (consisting only of
crystalloid solutions) was to keep the mean arterial pressure
within 80% of the baseline (before induction) for 90% of the
operating time. Urine output measurements continued until
at least 48 hours after EVAR, or until discharge. In accor-
dance with the authors’ standard protocol for elective EVAR,
aspirin and clopidogrel were administered on the day of
the procedure. Aspirin was discontinued on the 30th day,
whereas clopidogrel was continued as a life-long treat-
ment.22 Patients were asked to mobilise and eat and drink,
as tolerated, as soon as possible after the repair and were
usually discharged on day 2. In case the patient developed
AKI over the initial 48 hours after EVAR, they were subse-
quently reviewed by a nephrologist and further treatment
was decided based on that consultation. A blood transfusion
(packed red blood cells) was given if a patient’s haemoglobin
(Hb) was less than 8 g/dL or if the patient had a history of
cardiac disease and was symptomatic with a Hb of less than
10 g/dL.Deﬁnitions and study endpoints
In order to deﬁne AKI incidence and classify the different
stages of AKI, SCr and Urine Output (UO) measurements
were taken into account, within the space of 48 hours after
the completion of the procedure. The following criteria
were applied: Acute Kidney Injury Network (AKIN),23 and
Kidney Disease Improving Global Outcomes (KDIGO).19,20
The diagnosis of AKI was deﬁned as an absolute increase
in SCr of more than or equal to 0.3 mg/dL (26.4 mmol/L),
or a percentage increase in SCr of more than or equal to
50% (1.5-fold from baseline), or a reduction in urine output
to less than 0.5 mL/kg per hour for more than 6 hours e all
within the space of 48 hours after the completion of the
procedure. This represents the patient meeting the mini-
mum criteria for “stage 1” AKI as per the AKIN and KDIGO
deﬁnitions, and is in line with the current National Institute
of Health and Care Excellence (NICE) deﬁnition for diag-
nosing AKI.
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the 48 hour window), further serial SCr measurements were
obtained for a period of at least 7 days (1 week) after the
completion of the procedure or until necessary. Patients
were then classiﬁed into three different stages of AKI, ac-
cording to AKIN and KDIGO criteria staging. Stage 2 AKI was
deﬁned as 100e199% SCr rise within 7 days or a urine output
<0.5 mL/kg/h for>12 hours, and Stage 3 AKI was deﬁned as
200% SCr rise within 7 days or rise to>354 mmol/L with an
acute rise >44 mmol/L or a urine output <0.3 mL/kg/h for
>24 hours or anuria for >12 hours.
The primary study endpoint was incidence of AKI. The
secondary study endpoints included: stage of AKI as per AKIN
and KDIGO, SCr and eGFR (CKD-EPI formula) levels at 24 and
48 hours compared with baseline, as well as SCr and eGFR
levels at 7 days compared with baseline for those who
developed AKI. Additionally, a multivariate analysis (adjusted
for age, sex, AAA size, and established pre-operative cardio-
vascular risk-factors) was performed to evaluate the effect of
AKI on mortality and cardiovascular events during follow up.
To determine the latter, a composite “cardiovascular” sec-
ondary endpoint was calculated by adding the following:
death, non-fatal myocardial infarction, non-fatal stroke, non-
fatal peripheral vascular complication. All complications
were deﬁned according to the reporting standards for EVAR
by Chaikof et al.24 Hypercholesterolaemia was deﬁned as
baseline total cholesterol levels of>5 mmol/L. Hypertension
was deﬁned as patient taking antihypertensive medication at
recruitment or blood pressure exceeding 140/90 mmHg at
baseline.Table 1. Baseline characteristics for those with and without acute
kidney injury (AKI).
Variable AKI No AKI p
N 28 (18.8%) 121 (81.2%) e
Age, years 72  8 69  8 .7
Female sex 4 (14%) 12 (10%) .5
Smoking 21 (75%) 103 (85%) .3
Hypertension 19 (68%) 95 (79%) .2
Cholesterolaemia 16 (57%) 40 (33%) .02
Stroke 1 (4%) 8 (7%) 1.0
MI 2 (7%) 9 (7%) 1.0
PAD 9 (32%) 20 (17%) .07
Diabetes 8 (29%) 17 (14%) .09
Neck diameter, cm 2.2  0.2 2.1  0.3 .7
Statin use 20 (71%) 70 (58%) .2
Antiplatelet therapy 28 (100%) 121 (100%) 1.0Statistical analysis
Analyses were performed using the Statistical Package for
Social Sciences Version 21.0 (SPSS, Chicago, IL, USA).
Continuous parametric data are presented as mean 
standard deviation (SD) and categorical data are presented
as absolute values and percentages. Comparisons between
the study groups were performed using the independent or
paired (where applicable) samples t test for continuous
parametric variables and Pearson’s chi-square test for cat-
egorical variables. A multivariate analysis was performed
using binary logistic regression to assess the effect of
important risk factors at baseline on AKI incidence. Addi-
tionally, Cox regression was employed to assess the impact
of AKI on mortality and cardiovascular morbidity during
follow up (using the composite endpoint), together with
factors (at baseline) where statistical comparison disclosed
a p value <.1. Kaplan-Meier analysis and the log-rank test
were used to compare survival between those with and
without AKI during follow up. A p value level <.05 was
considered statistically signiﬁcant.SCr, mmol/L 107  35 79  14 <.001
eGFR, mL/kg/1.73 m2 61  20 75  9 <.001
Hb, g/dL 13.3  2 13.2  1.6 .2
BMI, kg/m2 30  5 27  4 .2
BMI ¼ body mass index; eGFR ¼ estimated glomerular ﬁltration
rate; Hb ¼ haemoglobin; MI ¼ myocardial infarction;
PAD ¼ peripheral arterial disease; SCr ¼ serum creatinine.RESULTS
Operative outcomes
149 patients were included (16 females, 11%; mean age:
69  8 years; mean AAA diameter: 6.0  1.1 cm),undergoing elective EVAR for an infra-renal AAA. None of
the procedures were converted to open repair and all an-
eurysms were successfully excluded on the completion
angiograms with no evidence of immediate endoleak. None
of the main renal arteries were covered by the endografts; a
total of eight accessory renal arteries were covered (2 of
these patients then developed AKI, p ¼ .65). None of the
patients had excessive calciﬁcation, thrombus, or severe
angulation at the level of the proximal neck24; none of the
patients had a neck length of <12 mm. The mean volume of
contrast used was 121  15 mL. This did not differ signiﬁ-
cantly between those who did and did not develop AKI
(120  15 mL vs. 121  14 mL, p ¼ .52). Only two patients
received a blood transfusion (packed red blood cells) within
7 days of the repair, one of whom then developed AKI.
None of the patients developed severe bleeding, hypo-
volaemic shock, or required inotropic support at any point
during the ﬁrst post-operative week.Primary endpoint
A total of 28 patients (18.8%) developed AKI. Table 1
summarizes the main characteristics for patients with and
without AKI.Secondary endpoints and events during follow up
Table 2 summarizes SCr and eGFR levels (renal outcomes) at
baseline, 24 hours, 48 hours, and 7 days after the
completion of the procedure. Overall, of those 28 patients
who developed AKI, 25 patients (89%) were classiﬁed as
stage 1 as per both the AKIN and KDIGO criteria and three
(11%) were staged as stage 2 as per both the AKIN and
KDIGO criteria; none were clustered as stage 3. None of the
patients required renal dialysis after the procedure
(throughout follow up). Mean SCr increased from
Table 2. Renal outcomes for groups with and without acute kidney injury (AKI).
Baseline 1 day 2 days 6 months
AKI SCr, mmol/L 107  36 166  53 130  43 117  39
eGFR, mL/kg/1.73 m2 61  20 39  16 51  20 58  21
No AKI SCr, mmol/L 80  14 82  15 86  16 80  16
eGFR, mL/kg/1.73 m2 75  9 75  10 74  11 75  10
eGFR ¼ estimated glomerular ﬁltration rate (CKD-EPI formula); SCr ¼ serum creatinine.
p value <.001 in all cases for between group comparisons (ANOVA testing).
Table 4. Cox regression for all cause mortality during follow up.
Variable p HR 95% CI
Age .001 1.305 1.107 1.537
Sex .995 0.994 0.163 6.045
PAD .473 0.575 0.127 2.608
Diabetes .369 2.104 0.415 10.682
Cholesterolaemia .942 0.951 0.246 3.681
AKI <.001 0.035 0.005 0.240
eGFR .299 1.027 0.977 1.080
AKI ¼ acute kidney injury; eGFR ¼ estimated glomerular ﬁltration
rate (CKD-EPI formula); PAD ¼ peripheral arterial disease.
Table 5. Cox regression for cardiovascular morbidity during follow
up.
Variable p HR 95% CI
Age .013 1.134 1.027 1.252
Sex .923 0.942 0.281 3.155
PAD .752 0.842 0.289 2.450
Diabetes .669 0.787 0.262 2.361
Cholesterolaemia .312 0.83 0.205 1.657
AKI <.001 0.021 0.004 0.111
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for those who developed AKI within 24 and 48 hours,
respectively (p < .001 in both cases). Mean eGFR (CKD-EPI
formula) decreased from 61  20 mL/min/1.73 m2 to
39  16 units and then 52  20 units for those who
developed AKI within 24 and 48 hours, respectively
(p < .001 in both cases). Twelve patients (8%) had a drop in
urine output below 0.5 mL/kg/hour for more than 6 hours
over the initial 2 ﬁrst post-operative days. On multivariate
analysis, only hypercholesterolaemia at baseline was asso-
ciated with AKI development (Table 3).
Mean follow up was 33  11 months. A total of 11 pa-
tients (7.4%) died during follow up and a total of 20 pa-
tients (13.4%) developed complications as per the
cardiovascular composite endpoint. Interestingly, nine
(32.1%) of the patients who developed AKI died during
follow up, and another 18 (64.3%) developed cardiovascular
complications. Those who developed AKI were more likely
to die (32.1% vs. 1.7%, p < .001) or develop cardiovascular
morbidity (as per the “composite endpoint” 64.3% vs. 1.7%,
p < .001) during follow up on univariate analysis; AKI was
also independently associated with death and cardiovas-
cular morbidity on multivariate survival analysis (Tables 4
and 5, Fig. 1). A total of eight type 2 endoleaks (5.3%)
and two type 1 endoleaks (1.3%) occurred during follow
up e all type 1 endoleaks occurred in patients who did not
develop AKI.Table 3. Determinants of acute kidney injury (AKI) incidence post-
operatively (multivariate analysis).
Variable p OR 95% CI
Age 0.435 0.966 0.885 1.054
Sex 0.542 1.800 0.273 11.876
Contrast load 0.757 1.007 0.965 1.050
Haemoglobin 0.116 0.730 0.493 1.081
Urea 0.115 0.748 0.521 1.073
Serum creatinine 0.142 0.962 0.913 1.013
eGFR 0.785 1.012 0.928 1.103
Smoking 0.722 0.792 0.220 2.856
AAA diameter 0.325 1.347 0.745 2.435
Neck diameter 0.983 0.970 0.059 15.854
Hypertension 0.219 2.189 0.627 7.640
Cholesterolaemia 0.012 0.208 0.061 0.712
Statin use 0.222 2.235 0.614 8.129
MI 0.720 0.675 0.079 5.802
PAD 0.982 0.983 0.219 4.407
Diabetes 0.694 0.742 0.167 3.291
AAA ¼ abdominal aortic aneurysm; eGFR ¼ estimated glomerular
ﬁltration rate, as per the CKD-EPI formula; MI ¼ myocardial
infarction; PAD ¼ peripheral arterial disease.DISCUSSION
This cohort study based on prospectively collected data
suggests that AKI after elective EVAR may be more common
than suggested by previous data, with an incidence ofeGFR .948 1.001 0.967 1.036
AKI ¼ acute kidney injury; eGFR ¼ estimated glomerular ﬁltration
rate (CKD-EPI formula); PAD ¼ peripheral arterial disease.
Figure 1. Kaplan-Meier survival curve comparing survival for those
with and without acute kidney injury (AKI) during follow up.
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operative complication, after any intervention, for a vari-
ety of reasons: impact on short and long-term mortality and
cardiovascular morbidity, longer hospital stay, increased
cost, and impact on long-term renal function.13e17 Previous
data suggested an incidence of 3e19% for elective EVARs e
the main reason for the wide variation is that a uniform
widely accepted deﬁnition of AKI has not been used
consistently in the current literature.13e17 Most in-
vestigators have not even included post-operative urine
output in deﬁning AKI. Serum creatinine (SCr) has mostly
been used as a marker of immediate post-operative renal
dysfunction (a rise of 25% or 50%) and then been reported
as “AKI incidence.”
Overall, immediate post-operative renal injury has a lower
incidence in EVAR compared with open repair in the majority
of series, using the aforementioned inconsistent criteria.25
However, three studies have documented a similar or more
pronounced incidence following EVAR e two of these
deﬁned AKI as a rise in SCr of more than 50% compared with
baseline and one as >30% compared with baseline. The
Dutch Randomized Endovascular Aneurysm Management
(DREAM) trial showed that peri-operative changes in SCr
were similar with no statistical differences in the incidence of
AKI (as per their deﬁnition) or need for dialysis.26 Another
prospective, non-randomized study, evaluating 485 patients
undergoing EVAR or open repair,27 disclosed a signiﬁcant
increase in SCr and a drop in creatinine clearance for EVAR
(from 1.0 [0.9e1.3] mg/dL to 1.08 [0.9e1.36] mg/dL, and
from 67.6 [51.3e85.10] mL/min to 66.7 [49.9e81.4] mL/
min), but not for open repair. An analysis of the National
Surgical Quality Improvement Program in the USA, including
6,516 patients (retrospective data), also showed that im-
mediate post-operative renal injury (deﬁned as >30% in-
crease in SCr concentration) in EVAR and open repair have
similar occurrence rates.28 A more recent update of this
analysis including 11,753 patients showed that “acute renal
failure” is less common in EVAR (0.4% vs. 2.7%, p< .001), but
it is unclear how “renal failure” was deﬁned.29
The mechanisms that may lead to renal dysfunction after
EVAR include: contrast administration (contrast induced
nephropathy or CIN30 - contrast administration leads to:
increased vasoconstrictive forces, decreased local prosta-
glandin and nitric oxide mediated vasodilatation, a direct
toxic effect on renal tubular cells by oxygen free radicals,
increased oxygen consumption, increased intra-tubular
pressure secondary to contrast induced diuresis, increased
urinary viscosity, and tubular obstruction), renal micro-
embolization during device deployment,31 complications
directly relating to the renal arteries, such as dissection or
coverage of the arterial oriﬁce,32 lower limb ischaemia and
subsequent ischaemia reperfusion syndrome,33 hypo-
volaemia, the presence of an inﬂammatory inﬁltrate (the
actual aneurysmal sac that is not excised such as in open
aneurysm repair),34 and various pre-morbid cardiovascular
risk factors.35
The RIFLE criteria were the ﬁrst universally accepted
criteria for AKI in 2002.36 However, more recently, the AcuteKidney Injury Network (AKIN),23 Kidney Disease Improving
Global Outcomes (KDIGO),19,20 and National Institute for
Health and Care Excellence (NICE)37 criteria have been
introduced. In this study AKI was deﬁned using the AKIN
and KDIGO deﬁnitions to reveal an incidence of 18.8%,
which makes AKI a common complication after EVAR.
Interestingly, the main predictors of AKI development were
eGFR levels and hypercholesterolaemia. Contrast load was
not directly associated with AKI, which means that contrast
induced renal injury is not the only underlying mechanism.
Also, none of the patients were found to have microemboli
into the renal parenchyma on the follow up CT scans. This
may be because none of the patients had a device with
suprarenal ﬁxation. Suprarenal ﬁxation can lead to deteri-
oration of renal function over the longer term after EVAR,
based on previous data38; however, sufﬁcient data are not
available currently regarding renal function in the immedi-
ate post-operative period after implantation of a device
with suprarenal ﬁxation.
One of the most important ﬁndings of the study is that
AKI is more prevalent among those with impaired renal
function before EVAR (baseline). Those who did go on to
develop AKI in this series had a signiﬁcantly lower eGFR at
baseline (61  20 vs. 75  9 units, p < 0.001, Table 1), even
though on multivariate analysis, eGFR or SCr levels were not
associated with the incidence of AKI. AKI development was
also associated with mortality and cardiovascular outcome
over a mean follow up of 33 months. It has been shown
previously that baseline eGFR levels are directly associated
with post-operative outcome after EVAR.39 Overall, this
study cannot specify whether AKI per se is the main
determinant of less favourable outcome in this subset of
the population undergoing EVAR. Indeed the patients who
did develop AKI were more likely to develop morbidity, but
their baseline renal function was also decreased in com-
parison. In any case, it is important to optimize the patient’s
renal function in the peri-operative period, especially those
with reduced renal function at baseline. Unfortunately,
there are a paucity of data regarding the prevention of AKI
in EVAR.40 Two signiﬁcantly underpowered randomized pi-
lot studies have reported no beneﬁt from N-acetylcysteine41
or hydration with sodium bicarbonate.42 Targeted renal
therapy43 and regional anaesthesia44 may be of beneﬁt, but
both have drawbacks and have not been widely adopted.
Aggressive hydration therefore remains the most important
intervention to prevent AKI in EVAR. Further studies are
urgently required to assess further methods as well as the
optimum way of providing hydration to this population.
The impact of AKI on longer term renal function is
another important point. In this series, those with AKI
dropped their eGFR by a mean of 3 units (Table 2), whereas
patients without AKI had a stable eGFR 6 months after the
repair. It has been shown previously that EVAR may be
associated with a signiﬁcant drop in eGFR, up to 6 units per
annum for the ﬁrst post-operative year.38 This reduction in
renal function slows down after the ﬁrst year. As a result,
alleviating the peri-operative insult will improve longer-
term function overall as well.45 This study is limited by
Incidence of Acute Kidney Injury 539the fairly small number of patients included and the fact
that even though it is based on prospectively collected data,
it represents a retrospective analysis. However, it has
employed consistent and widely accepted AKI deﬁnitions to
assess the incidence of the pathology after EVAR in a sys-
tematic manner. It is also not confounded by the use of
suprarenal graft ﬁxation in part of the population under
investigation; previous studies have combined the two
modes of ﬁxation in their analyses, which can skew ﬁnd-
ings.38 The study is also limited by the urine output mea-
surements, after removal of the urinary catheter, not being
adequately documented in 100 patients, who were subse-
quently excluded. This may have introduced selection bias
at baseline.
Acute kidney injury after EVAR is common and is asso-
ciated with increased mortality and morbidity. Further
studies are urgently required to assess the impact of AKI on
longer term results and examine preventive strategies.CONFLICT OF INTEREST
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